


03C0

#5

MAIL DATE CANCELLED



Patent  
Page 1 of 3

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Application: Claes Ohlsson et al.  
Serial No. : 09/994,292  
Filed : November 26, 2001  
For : ESTROGEN RECEPTORS  
Examiner :  
Attorney Docket : 102296-100  
Group Art Unit :  
Confirmation No. : 8841

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an  
envelope addressed to: Assistant Commissioner for Patents,  
Washington, D.C. 20231 on 7 FEB 2002.

By Todd E. Garabedian  
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicant(s)

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully  
requested to consider the references cited on attached Form PTO-  
1449. A copy of each reference (if not previously submitted) is  
enclosed. It is respectfully requested that the information be  
expressly considered during the prosecution of this application,  
and that the reference(s) be made of record therein and appear  
among the "References Cited" on any patent to issue therefrom.

- [X] 1. This Information Disclosure Statement is being filed  
within three months of the U.S. filing date OR before the  
mailing date of a first Office Action on the merits. No  
certification or fee is required.

[ ] 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

[ ] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).

[ ] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).

[ ] Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.

[ ] A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).

[ ] 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.

[ ] a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [ ] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e) (2).
- [ ] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [ ] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

CLAES OHLSSON ET AL.

By



Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicants

WIGGIN & DANA  
One Century Tower  
New Haven, CT 06508-1832

Telephone : (203) 498-4400  
Telecopier: (203) 782-2889

Date: 7 FEB 2002



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application : Claes Ohlsson et al.  
Serial No. : 09/994,292  
Filed : November 26, 2001  
For : ESTROGEN RECEPTORS  
Examiner :  
Attorney Docket : 102296-100  
Group Art Unit :  
Confirmation No. : 8841

\* \* \* \* \*

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as first class mail in an  
envelope addressed to: Assistant Commissioner for Patents,  
Washington, D.C. 20231 on 7 FEB 2002.

By

Todd E. Garabedian, Ph.D.

Registration No. 39,197

Attorney for Applicant(s)

\* \* \* \* \*

INFORMATION DISCLOSURE LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned represents that the closest art of which he  
is presently aware has been cited herein and understands that  
this statement shall not be construed as a representation that  
no better art exists or that a thorough patentability search has  
been made.


The undersigned further represents that the filing of this  
Information Disclosure Statement shall not be construed to be an  
admission that the information cited in the Statement is, or is  
considered to be, material to patentability as defined in 37  
C.F.R. § 1.56(b).

1. PCT WO 00/76529 A2 filed June 12, 2000.
2. PCT WO 00/70079 A1 filed May 10, 2000.
3. PCT WO 00/66767 filed April 28, 2000.
4. PCT WO 00/19994 A1 filed October 1, 1999.
5. U.S. Patent No. 5,183,736 issued February 2, 1993  
to Pfahl et al.
6. CAS Abstract No. 2000:832646, Ohlsson et al.,  
Biochem. Biophys. Res. Commun. (2000), 278(3),  
pp. 640-645.
7. CAS Abstract No. 2000:818447, Heine et al., Proc.  
Natl. Acad. Sci. USA (2000), 97(23), pp. 12729-12734.
8. CAS Abstract No. 1998:206686, Ke et al., Endocrinology  
(1998), 139(4), pp. 2068-2076.
9. PCT WO 00/39120 filed December 30, 1999.
10. PCT WO 00/31112 filed November 18, 1999.

If the Examiner has any questions or feels that a discussion with Applicants' representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicants' undersigned representative at the telephone number listed below.

Respectfully submitted,

**CLAES OHLSSON ET AL.**

By   
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicant(s)

WIGGIN & DANA  
One Century Tower  
New Haven, CT 06508

Date: 7 FEB 2002

Telephone: (203) 498-4400  
Fax: (203) 782-2889